Albany, NY -- (SBWIRE) -- 02/05/2019 -- Global Hypertrophic Cardiomyopathy Therapeutics Market – Key Trends
With heart diseases emerging as one of the most common causes of mortality among men and women worldwide, Transparency Market Research (TMR) expects the demand for hypertrophic cardiomyopathy (HCM) therapeutics to surge considerably. Furthermore, the market is expected to gain significant impetus from successful government interventions aimed at spreading awareness about hypertrophic cardiomyopathy.
Obtain Report Details @
https://www.transparencymarketresearch.com/hypertrophic-cardiomyopathy-therapeutics-market.html
TMR projects the global HCM therapeutics market to expand at a moderate 1.4% CAGR between 2015 and 2023. Despite witnessing positive opportunities, the rising demand for advanced medical devices could threaten the market's growth to an extent. Nevertheless, since the majority of HCM drugs are yet to get approved, the hypertrophic cardiomyopathy therapeutics market is likely to gain momentum post their approval in the near future.
According to TMR, the global hypertrophic cardiomyopathy therapeutics market is expected to reach US$1.37 bn in 2023, from US$1.2 bn in 2015. The leading players in the market are likely to capitalize on the untapped opportunities in the healthcare sector of emerging economies to expand their footprint.
Request for Sample Copy of Report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=7553
Rising Use of Calcium Channel Blockers Being Witnessed in Obstructive HCM Treatment
Antiarrhythmic drugs, anti-coagulating agents, calcium channel blockers, and beta blockers are the most recommended therapies for the treatment of HCM. By drug class, the calcium channel blockers segment held the leading share of 37.4% in the HCM therapeutics market in 2014. This drug provides an effective alternative to beta-blocker therapy particularly used in obstructive HCM treatment. As per TMR, the calcium channel blockers segment is expected to rise at a CAGR of 1.8% from 2015 to 2023.
The beta adrenergic blocking agents emerged as the second-largest segment in 2014. The most common beta adrenergic blocking agents preferred in HCM treatment include atenolol, metoprolol, propranolol, and sotalol.
Request Report Brochure @
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=7553
Due to the increasing sedentary lifestyle and unhealthy choices, experts project the incidence of heart disease to rise considerably in the forthcoming years. This will subsequently boost demand for HCM therapeutics through the forecast period.
About Transparency Market Research
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Contact Us
Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: www.transparencymarketresearch.com